EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer

Lena Weiss, Sebastian Stintzing, Arndt Stahler, C Benedikt Westphalen, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Edin Al-Batran, Tobias Heintges, Christian A Lerchenmüller, Christoph Kahl und 8 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115399 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Lena Weiss und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, LMU Klinikum, University of Munich, Munich, Germany. Electronic address: Lena.Weiss@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Molecular Targeted Therapy, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMolecular Targeted TherapyBiomarkers, TumorHumansMaleFemaleMiddle AgedCetuximabBevacizumabAgedRetrospective StudiesFluorouracilLeucovorinCamptothecinAdultProto-Oncogene Proteins B-rafHigh-Throughput Nucleotide Sequencingras ProteinsErbB ReceptorsAged, 80 and overDNA Mismatch Repair

Stichwörter der Autor:innen

HyperselectionMetastatic colorectal cancerNext generation sequencingPrecision medicineTargeted therapy

Substanzen

CetuximabBevacizumabFluorouracilLeucovorinCamptothecinBiomarkers, TumorProto-Oncogene Proteins B-rafBRAF protein, humanras ProteinsErbB Receptors

Autor:innen und Institutionen

  • Department of Medicine III, LMU Klinikum, University of Munich, Munich, Germany. Electronic address: Lena.Weiss@med.uni-muenchen.de.
  • Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin und Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Cancer Immunology, Berlin, Germany.
  • Department of Medicine III, LMU Klinikum, University of Munich, Munich, Germany; Comprehensive Cancer Center Munich, LMU Klinikum, University of Munich, Munich, Germany.
  • Praxis für Hämatologie/Onkologie, MVZ St. Marien, Amberg, Germany.
  • Oncological Practice, Ravensburg, Germany.
  • Department of Hematology and Oncology, Klinikum Bayreuth GmbH, Bayreuth, Germany and Comprehensive Cancer Center-EMN, Erlangen, Germany.

Zitieren

APA

Weiss, L., Stintzing, S., Stahler, A., Benedikt Westphalen, C., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S. E., Heintges, T., Lerchenmüller, C. A., Kahl, C., Seipelt, G., Kullmann, F., Heinrich, K., Holch, J. W., Alig, A., Jung, A., Modest, D. P., & Heinemann, V. (2025). Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115399

Vancouver

Weiss L, Stintzing S, Stahler A, Benedikt Westphalen C, von Weikersthal LF, Decker T, et al. Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115399

BibTeX
@article{Weiss2025,
  author = {Weiss, Lena and Stintzing, Sebastian and Stahler, Arndt and Benedikt Westphalen, C and von Weikersthal, Ludwig Fischer and Decker, Thomas and Kiani, Alexander and Vehling-Kaiser, Ursula and Al-Batran, Salah-Edin and Heintges, Tobias and Lerchenmüller, Christian A and Kahl, Christoph and Seipelt, Gernot and Kullmann, Frank and Heinrich, Kathrin and Holch, Julian Walter and Alig, Annabel and Jung, Andreas and Modest, Dominik Paul and Heinemann, Volker},
  title = {Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115399}
}
Kostenlos starten →